AZD-1222
- Listing at source
- Listed
- Drug name
- AZD-1222
- astra zeneca
- Astra Zeneca
- Astra-Zeneca
- astrazeneca
- Astrazeneca
- AstraZeneca
- azd 1222
- AZD 1222
- azd1222
- AZD1222
- chadox 1 s recombinant
- ChAdOx-1-S[recombinant]
- chadox1 ncov 19
- chadox1 ncov 19 0 5ml 3 5 6 5x10 10vp late vaccine lv
- chadox1 ncov 19 0 5ml 3 5 6 5x10 10vp late vaccine two lvt
- chadox1 ncov 19 0 5ml boost
- chadox1 ncov 19 0 5ml prime
- chadox1 ncov 19 abs 260
- chadox1 ncov 19 astra zeneca
- chadox1 ncov 19 qpcr
- ChAdOx1 nCov-19
- ChAdOx1 nCoV-19
- ChAdOx1 nCoV-19 (Abs 260)
- ChAdOx1 nCoV-19 (qPCR)
- ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)
And 20 more, listed on the interactive page.
- FDA ingredient codes (UNII)
- B5S3K2V0G8
Related records
Trials (36)
- A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
- A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults
- A Study of a Candidate COVID-19 Vaccine (COV001)
- A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
- A Study of Intranasal ChAdOx1 nCOV-19
- A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222
- A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
- Adaptive Immune Response to COVID-19 Vaccination
- Antibody Response to COVID-19 Vaccines in Liver Disease Patients
- AZD1222 Vaccine for the Prevention of COVID-19
- COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
- COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection
- COVID-19 VACCINE SAFETY AND EFFECTIVENESS
- COVID-19 Vaccines Safety Tracking (CoVaST)
- Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death
- EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19
- Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination